급성 전골수구성백혈병에서 RARα/PML융합전사 발현의 RT-PCR을 이용한 연구

어완규,김영일,김정희,김시영,윤휘중,조경삼 大韓血液學會 1995 大韓血液學會誌 Vol.30 No.3

Diffuse Large B-cell Lymphomas의 예후인자로서의 혈청 B2-microglobulin

어완규,신성훈 고신대학교(의대) 고신대학교 의과대학 학술지 2006 고신대학교 의과대학 학술지 Vol.21 No.1

Background: This study was undertaken to see whether serum 公 2-microglobulin (B2M) could be used as a prognostic factor or not in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Methods: One hundred and forty-six consecutive patients with previously untreated DLBCL were participated in this study between 1995 and 2004. Serum B2M was measured by a radioimmunoassay in pretreatment serum samples of patients with DLBCL. Patients were then treated with CHOP or equivalent regimens with or without radiotherapy. Results: Serum B2M was available in 127 out of 146 patients enrolled. The median age was 54 years (15-80). Serum B2M levels greater than 2.5 mg/L were found in 27/127 (21.3%) patients. Higher serum levels were associated with old age,high serum LDH,poor performance status, increased number of extranodal site(s),advanced stage, constitutional symptom, bone marrow involvement,and high International Prognostic Index (P=0.001,0.000, 0.000, 0.024, 0.000, 0.010, 0.040, and 0.000, respectively). The complete response rate was 40.7% vs. 68.0% for patients with serum B2M levels greater than 2.5 mg/L vs. control (P=0.010). The median overall survival was 11 months vs, 74 months for patients with serum B2M levels greater than 2.5 mg/L vs. control (P-0.0000). Conclusions: Serum B2M level was a good predictor of complete response and overall survival in patients with previously untreated DLBCL and could be used as a prognostic factor.

폐경전후 및 폐경후 골감소에서 호르몬대체요법과 Fluocalcic Effervescent 병합치료 후 골밀도 및 골대사의 생화학 지표의 변화

어완규,이창원 고신대학교(의대) 고신대학교 의과대학 학술지 2004 고신대학교 의과대학 학술지 Vol.19 No.1

Background : Sodium fluoride stimulates bone formation and has been used to treat osteoporosis for decades despite debate about the antifracture efficacy. For women with low bone mass, the ideal therapy should not only inhibit bone resorption but stimulatneously stimulate bone formation to increase the bone mass above the fracture threshold. We thus performed an intervention study to investigate the effect of a low dose fluoride prospectively, in combination with HRT, on bone mineral density (BMD) and biochemical markers of bone turnover. Methods : Thirty perimenopausal or postmenopausal osteopenic women were enrolled, and were treated with Fluocalcic effervescent (disodiummonofluorophosphate [MFP] 100mg + calcium carbonate 1,250mg) 1 tablet BID and conjugated equine estrogen (HRT) 0.625mg QD for 12 months in Department of Internal Medicine, Kosin University Gospel Hospital from January 2001 to December 2002. BMD and chemical markers of bone turnover, serum alkaline phosphatase, serum osteocalcin, and urine deoxypyridinoline (DPD), were evaluated before and 12 months after starting treatment. Results : Serum alkaline phosphatase, serum osteocalcin, and urine DPD after 12 months were not significantly different from those of pre-treatment values. The post-treatment BMD's were correlated with pretreatment BMD's, but they were not correlated with all the pretreatment chemical markers of bone metabolism. Changes of the BMD of L2-L4 were not correlated with the changes of chemical markers except urine DPD. Pretreatment markers, BMD of L2-L4, serum osteocalcin, serum alkaline phosphatase, and FSH were correlated with changes in BMD of L2-L4. There was no chemical markers correlated with the change in BMD of femoral neck. Conclusion : Twelve-month treatment with MFP and HRT was not associated with improvement in BMD. Pretreatment markers, BMD of L2-L4, serum osteocalcin, serum alkaline phosphatase, and FSH may predict changes in the BMD of L2-L4.

공격성 비호지킨 림프종의 예후인자로서의 혈청 LDH

어완규,이지현,김종철 고신대학교(의대) 고신대학교 의과대학 학술지 2004 고신대학교 의과대학 학술지 Vol.19 No.1

Introduction : The purpose of this study was to find the prognostic factors influencing overall survival in patients with aggressive non-Hodgkin's lymphoma. Methods : Eighty eight patients, all diagnosed with aggressive lymphoma and treated with conventional chemotherapy, were registered in the section of hematology/medical oncology, Gospel Hospital, Busan, Korea. We analyzed the response rate and survival time by the pre-treatment several variables including age, serum LDH, performance state, number of extranodal site, stage, B-symptom, bone marrow involvement, international prognostic index (IPI), and serum beta2-microglobulin (B2M) to identify the prognostic variables in the patients. Results : The median age was 53 years. Forty-five (56.9%) patients achieved complete response, and 26 (32.(%) achieved partial response to conventional chemotherapy. Of the variables, serum LDH, performance status, extranodal involvement, stage, IPI, and serum B2M were predictive of complete response (P=0.000, 0.005, 0.022, 0.002, 0.000, 0.035, respectively) Estimated overall survival at 5 years was 56.5%. By univariate analysis, 6 variables significantly influenced overall survival: serum LDH, performance status, stage, serumB2M, IPI, and response to chemotherapy (P=0.0005, 0.0022, 0.0022, 0.0161, 0.0131, 0.0000, respectively). By multivariate analysis, only serum LDH was the significant variable (P=0.001). Conclusion : Serum LDH appears to be a useful marker for predicting survival in patients with aggressive non-Hodgkin's lymphoma treated with conventional chemotherapy.

유년형 난소 과립막 세포종 2예

어완규,김흥열,김홍배 고신대학교 의과대학 2008 고신대학교 의과대학 학술지 Vol.23 No.2

난소의 성기삭-간질 종양은 전체 난소 종양의 약 5~8% 를 차지하는 드문 종양으로서 그 중 약 70%는 과립막 세포종이다. 대부분 30세 이전에 발생하는 유년형 과립막 세포종은 전형적인 성인형 과립막 세포종에 비해서 임상적 및 병리학적 측면에서 매우 다른 양상을 나타낸다. 유년형 과립막 세포종은 대부분 좋은 예후를 나타내지만, 종양이 진행된 경우에는 병기, 종양의 크기, 피막 파열 여부, 핵의 비정형 정도, 유사분열 정도와 관련되어 나쁜 임상적 예후를 나타낸다. 유년형 과립막 세포종은 병기가 낮은 경우 수술이 최상의 치료 방법이지만, 병기가 높거나 재발된 종양에 대한 치료 방법은 아직 명확하지 않다. 저자들은 난소의 유년형 과립막 세포종 2예를 경험하였기에 문헌고찰과 함께 보고하는 바이다. Sex cord-stromal tumors of the ovary are rare neoplasms that account for about 5~8% of all ovarian malignancies, and about 70% of those are granulosa cell tumors. Juvenile granulosa cell tumor (JGCT), which occurs most frequently in the first two decades, has distinct differences from adult granulosa cell tumor (AGCT) with regard to clinical and pathological features. The prognosis of JGCT in children is good in most cases, but tumor with more advanced disease has worse clinical outcome correlated with its stage, tumor size, presence of ruptures, grade of nuclear atypia, and degree of mitotic activity. The best treatment choice for low stage JGCT is surgery, but those for advanced stage JGCT or recurrent tumor have not yet been determined clearly. We present two cases of JGCT with brief review of literatures.

폐경기 여성에서 티볼론, 칼시토닌, 칼슘제제 주기적 병용 투여에 따른 골밀도 효과

어완규,정혁,김흥열 대한골다공증학회 2008 Osteoporosis and Sarcopenia Vol.6 No.1

목적: 폐경 후 골다공증 여성에서 3개월 간격으로 티볼론, 칼시토닌, 칼슘을 병합 투여하는 것을 3개월 간격으로 두 번 반복 후 골밀도의 변화를 보고자 하였다. 방법: 2007년 1월부터 10월까지 골다공증으로 티볼론과 칼시토닌, 칼슘 병합요법을 시행한 269명 중 적어도 1년 이상 추적 관찰이 가능했던 101명이 분석대상이 되었으며 치료 전 후 골밀도와 혈액검사 상 칼슘, 인, 알칼라인 포스파타아제와 요 중 칼슘/크레아티닌 비를 비교하였다. 결과: 요추에서의 골밀도는 0.63g/cm2에서 0.66g/cm2로 증가하였으나 골반에서의 골밀도는 증가하지 않았으며(femur neck: 0.61g/cm2 to 0.61g/cm2, trochanter: 0.56g/cm2 to 0.49g/cm2, Ward's triangle: 0.38g/cm2 to 0.39g/cm2), 통계적으로 모두 유의하지 않았다. 혈액검사와 요 검사상 골대사와 관련된 지표들 역시 모두 통계적으로 유의한 변화를 보이지 않았다. 결론: 폐경 후 골다공증 여성에서 주기적인 티볼론과 칼시토닌, 칼슘 병합요법은 골밀도 상승효과를 가져오지 않는다.

심낭삼출의 원인과 임상경과에 관한 연구

어완규,이석권,최철준,조정휘,김권삼,김명식,송정상,배종화 대한순환기학회 1990 Korean Circulation Journal Vol.20 No.2

철결핍성 빈혈치료제의 약리와 생체내 동태

어완규 약업신문사 1997 의약정보 Vol.1997 No.10

Diffuse Large B-cell Lymphomas의 예후인자로서의 혈청 β2-microglobulin

어완규,신성훈 KOSIN UNIVERSITY COLLEGE OF MEDICINE 2006 高神大學校 醫學部 論文集 Vol.21 No.1

Background: This study was undertaken to see whether serum β2-microglobulin (B2M) could be used as a prognostic factor or not in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Methods: One hundred and forty-six consecutive patients with previously untreated DLBCL were participated in this study between 1995 and 2004. Serum B2M was measured by a radioimmunoassay in pretreatment serum samples of patients with DLBCL. Patients were then treated with CHOP or equivalent regimens with or without radiotherapy. Results: Serum B2M was available in 127 out of 146 patients enrolled. The median age was 54 years (15-80). Serum B2M levels greater than 2.5 mg/L were found in 27/127 (21.3%) patients. Higher serum levels were associated with old age, high serum LDH, poor performance status, increased number of extranodal site(s), advanced stage, constitutional symptom, bone marrow involvement, and high International Prognostic Index (P=0.001, 0.000, 0.000. 0.024, 0.000, 0.010, 0.040, and 0.000, respectively). The complete response rate was 40.7% vs. 68.0% for patients with serum B2M levels greater than 2.5 mg/L vs. control (P=0.010). The median overall survival was 11 months vs. 74 months for patients with serum B2M levels greater than 2.5 mg/L vs. control (P=0.0000). Conclusions: Serum B2M level was a good predictor of complete response and overall survival in patients with previously untreated DLBCL and could be used as a prognostic factor.

공격성 비호지킨 림프종의 예후인자로서의 혈청 LDH

어완규,이지현,김종철 고신대학교 의학부 2004 高神大學校 醫學部 論文集 Vol.19 No.1

Introduction: The purpose of this study was to find prognostic factors influencing overall survival in patients with aggressive non-Hodgkin's lymphoma. Methods: Eighty eight patients, all diagnosed with aggressive lymphoma and treated with conventional chemotherapy, were registered in the section of hematology/medical oncology. Gospel Hospital. Busan. Korea. We analyzed the response rate and survival time by the pre-treatment several variables including age, serum LDH, performance state, number of extranodal site, stage, B-symptom, bone marrow involvement, international prognostic index (IPI), and serum beta2-microglobulin (B2M) to identify the prognostic variables in the patients. Results: The median age was 53 years. Forty-five (56.9%) patients achieved complete response, and 26 (32.9%) achieved partial response to conventional chemotherapy. Of the variables serum LDH, performance status, extranodal involvement, stage, IPI, and serum B2M were predictive of complete response (P=0.000, 0.005, 0.022, 0.002, 0.000, 0.035, respectively). Estimated overall survival at 5 years was 56.5%. By univariate analysis, 6 variables significantly influenced overall survival: serum LDH, performance status, stage, serum B2M, IPI, and response to chemotherapy (P=0.0005, 0.0022, 0.0022, 0.0161, 0.0131, 0.0000, respectively). By multivariate analysis only serum LDH was the significant variable(P=0.001). Conclusion: Serum LDH appears to be a useful marker for predicting survival in patients with aggressive non-Hodgkin's lymphoma treated with conventional chemotherapy.